Cardiorenal axis and congestion

09/07/23 • 19 min

With Wilfred Mullens, Hospital Oost-Limburg (ZOL) and Hasselt University - Belgium & Alberto Esteban-Fernández, Hospital Universitario Severo Ochoa y Alfonso X El Sabio University - Spain.

This podcast addresses some of the main developments in congestion management in heart failure patients, especially those with cardiorenal syndrome. We discuss the ADVOR and CLOROTIC trials and their implications for clinical practice.

With Wilfred Mullens, Hospital Oost-Limburg (ZOL) and Hasselt University - Belgium & Alberto Esteban-Fernández, Hospital Universitario Severo Ochoa y Alfonso X El Sabio University - Spain.

Previous Episode

Preventing Heart Failure From Evidence to Action

With Amitai Segev, Sheba Medical Center, Ramat Gan - Israel and Massimo Francesco Piepoli, IRCCS San Donato Polyclinic, San Donato Milanese - Italy

In this episode of HFA Cardio Talk, we dive into the world of heart failure prevention with our esteemed guest, Prof. Massimo Piepoli, an eminent figure in preventive cardiology, as he is interviewed by Dr. Amitai Segev. Join us as we discuss the importance of heart failure prevention in modern cardiology, explore practical evidence-based measures, and address key topics in the field. Tune in for an engaging and informative conversation filled with valuable insights and actionable tips for promoting cardiovascular health.

Next Episode

Heart failure insights from the ESC congress 2023, Amsterdam, the Netherlands

With Henrike Arfsten, University of Vienna, Vienna - Austria, Juan Pablo Kaski, University College London, London - United Kingdom, Mateusz Sokolski, Wroclaw Medical University, Wroclaw - Poland, Jozine ter Maaten, University Medical Center Groningen, Groningen - the Netherlands, Peter van der Meer, University Medical Center Groningen, Groningen - the Netherlands, Antonio Cannata, King's College London, London - United Kingdom & Theresa McDonagh, King's College Hospital, London, United Kingdom.

This podcast discusses two new guidelines and the results of two hot line presentation all presented at the ESC congress 2023 in Amsterdam, the Netherlands. First, Prof. Kaski shares highlights from the new and first ESC cardiomyopathy guidelines. Second, Prof. van der Meer discusses the results from the STEP HFpEF study in which semaglutide showed beneficial effect on weight, 6MWT and a win ratio compared to placebo in patients with the obesity phenotype of HFpEF. Next, Dr. ter Maaten discusses the results of the first randomized trial investigating the effect of natriuresis guided diuretic therapy in acute heart failure, as already incorporated in the guidelines. Finally, Prof. McDonagh walks us through the update of the ESC heart failure guidelines. The podcast is concluded with a brief discussion of some HFA Young highlights at the congress.